1417529-54-4

Basic information

• Product Name: 6-(1-bromoethyl)-3-(2-ethoxyphenyl)-4H-[1,2,4]triazin-5-one
• Synonyms: 6-(1-bromoethyl)-3-(2-ethoxyphenyl)-4H-[1,2,4]triazin-5-one
• CAS NO: 1417529-54-4
• Molecular Weight: 324.177
• Mol File: 1417529-54-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 6-(1-bromoethyl)-3-(2-ethoxyphenyl)-4H-[1,2,4]triazin-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(1-bromoethyl)-3-(2-ethoxyphenyl)-4H-[1,2,4]triazin-5-one(1417529-54-4)
• EPA Substance Registry System: 6-(1-bromoethyl)-3-(2-ethoxyphenyl)-4H-[1,2,4]triazin-5-one(1417529-54-4)

Safety Data

• Hazardous Substances Data: 1417529-54-4(Hazardous Substances Data)

Upstream product

• 1417529-52-2 3-(2-ethoxyphenyl)-6-ethyl-4H-[1,2,4]triazin-5-one 

Downstream Products

• 1417529-59-9 N-{1-[3-(2-ethoxy-phenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]ethyl}acetamide 
• 1417529-61-3 N-{1-[3-(2-ethoxyphenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]ethyl}propioamide 
• 927690-90-2 N-{1-[3-(2-ethoxyphenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]ethyl}butyroamide 
• 1417529-64-6 N-{1-[3-(2-ethoxy-phenyl)-5-oxo-4,5-dihydro-[1,2,4] triazin-6-yl]ethyl}benzamide 
• 1417529-65-7 N-{1-[3-(2-Ethoxyphenyl)-5-oxo-4,5-dihydro-[1,2,4]triazin-6-yl]ethyl}oxalamic acid ethyl ester 
• 224789-20-2 2-(2-Ethoxyphenyl)-5,7-dimethyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1417529-66-8 2-(2-ethoxyphenyl)-5-methyl-7-ethyl-imidazo[5,1-f][1,2,4]-triazin-4(3H)-one 
• 224789-21-3 2-(2-ethoxy-phenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one 
• 1417529-69-1 2-[(2-ethoxy-5(4-ethylpiperazine-1-sulphonyl)phenyl)]-7-ethoxycarbonyl-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one 
• 1417529-56-6 C₁₃H₁₆N₄O₂ 

Relevant articles and documents

Alternative method for the synthesis of imidazo[5,1-f][1,2,4]triazin-4(3H)- one - A substrate for the preparation of phosphodiesterase (5) inhibitors

Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, as isosteres of purine, are of interest for pharmaceutical research as potential substrates for the synthesis of cGMP-PDE5 inhibitors. We present a novel, alternative method for the synthesis of imidazotriazinones, that differs from the previously reported ones with respect to the method of construction of the triazinone ring in the molecule. The key step in our approach is condensation of an appropriate α-keto-ester with amidrazones, leading to the triazinone heterocycle. Several different substituted imidazolotriazinones have been synthesized in this manner.